TORRANCE, Calif., Sept. 3, 2019 /PRNewswire/ -- Emmaus Life
Sciences, Inc. (Nasdaq: EMMA), a leader in sickle cell disease
treatment, announced today the allowance of patent application
number 12860587.0, directed to the treatment of diverticulosis, by
the European Patent Office. The allowance of this application
follows the issuance of corresponding patents in the United States, Japan, Australia, Mexico, China, Indonesia, South
Korea and Russia. Patent
applications are currently pending in various jurisdictions around
the world, including Brazil and
India.
The allowed European application reports a significant reduction
in the number of intestinal diverticula, the primary indicator of
diverticulosis, through the therapeutic application of
-pharmaceutical-grade L-glutamine (PGLG). There are no commercial
therapies that claim an ability to reduce intestinal diverticula at
the present time.
"We have seen the tremendous therapeutic potential of PGLG
through the efficacy of Endari® in treating sickle cell disease,
and are excited to expand its application across additional
indications to address a range of unmet medical needs, including
the treatment of diverticulosis," said Dr. Yutaka Niihara, M.D., M.P.H., Chairman and Chief
Executive Officer of Emmaus Life Sciences. "As we continue to
further our research and product development efforts, these patents
will allow us to protect our intellectual property moving
forward."
The covered invention is directed to methods and/or compositions
for the treatment of diverticulosis. It is more specifically
directed to compositions including PGLG or uses of such
compositions in the treatment of diverticulosis. Diverticulosis
refers to a condition where pouches (i.e., diverticula) form along
the colon wall. Over time, some people get an infection in the
pouches (diverticulitis). Epidemiological studies indicate that the
prevalence of this disease is increasing worldwide. It is estimated
that at least 50% of the population over the age of 60 in
the United States, Europe and Australia have diverticulosis.
Emmaus announced the initiation of the company's Pilot/Phase 1
clinical study on the treatment of diverticulosis with PGLG on
July 8, 2019.
About Endari® (L-glutamine
oral powder)
Indication - Endari is indicated to reduce the acute
complications of sickle cell disease in adult and pediatric
patients five years of age and older.
Important Safety Information - The most common adverse
reactions (incidence >10 percent) in clinical studies were
constipation, nausea, headache, abdominal pain, cough, pain in
extremities, back pain, and chest pain.
Adverse reactions leading to treatment discontinuation included
one case each of hypersplenism, abdominal pain, dyspepsia, burning
sensation, and hot flash.
The safety and efficacy of Endari in sickle cell disease
patients younger than five years of age have not been
established.
For more information, please see full Prescribing Information of
Endari at: www.ENDARIrx.com/PI.
About Emmaus Life Sciences
Emmaus Life Sciences, Inc.,
is a commercial-stage biopharmaceutical company engaged in the
discovery, development, marketing and sale of innovative treatments
and therapies, including those in the rare and orphan disease
categories. For more information, please
visit www.emmauslifesciences.com.
Company Contacts:
Emmaus Life Sciences, Inc.
Joseph (Jay) C. Sherwood III
Chief Financial Officer
(310) 214-0065 ext. 3005
jsherwood@emmauslifesciences.com
George Sekulich
Senior Vice President of Global Commercialization
(310) 214-0065 ext. 1010
gsekulich@emmauslifesciences.com
Media Contacts:
Russo Partners
David Schull or Caroline Cunningham
(858) 717-2310
david.schull@russopartnersllc.com
caroline.cunningham@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/emmaus-life-sciences-granted-european-patent-for-use-of-pharmaceutical-grade-l-glutamine-in-treating-diverticulosis-300910406.html
SOURCE Emmaus Life Sciences
